NASDAQ:GERN
Geron Corporation Stock News
$3.35
-0.130 (-3.74%)
At Close: May 28, 2024
Recap: Geron Q2 Earnings
04:45pm, Monday, 16'th Aug 2021
Shares of Geron (NASDAQ:GERN) rose 2.5% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 50.00% over the past year to ($0.09), which missed
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported updates on the IMerge Phase 3 trial in lower risk MDS and financ
Geron to Announce Second Quarter 2021 Financial Results on August 16, 2021
04:30pm, Thursday, 05'th Aug 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron to Announce Second Quarter 2021 Financial Results on August 16, 2021
Do Options Traders Know Something About Geron (GERN) Stock We Don't?
09:47am, Monday, 21'st Jun 2021
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
Why Geron Stock Is Soaring Today
11:40am, Friday, 18'th Jun 2021
Investors are cheering the company's encouraging phase 2 data.
Geron Stock Trading Is Higher On Reinforcing Imetelstat's Approach For Myelofibrosis Treatment, With Data Publication In Journal
06:31am, Friday, 18'th Jun 2021
Geron Corporation (NASDAQ: GERN) stock is trading higher during the premarket in reaction to data publication from the IMbark Phase 2 trial of imetelstat for myelofibrosis (MF) in the Journal of Cl
GERN Stock Price Increases Over 30% Pre-Market: Why It Happened
05:18am, Friday, 18'th Jun 2021
The stock price of Geron Corporation (NASDAQ: GERN) increased by over 30% pre-market. This is why it happened.
Geron Announces Publication of IMbark Phase 2 Data in Journal of Clinical Oncology
04:30pm, Thursday, 17'th Jun 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the publication of data from the IMbark Phase 2 clinical trial
Geron Reports Two Presentations at Virtual European Hematology Association Annual Congress
04:30pm, Monday, 14'th Jun 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses
Geron Announces Two Presentations at Upcoming European Hematology Association Annual Congress
10:56am, Wednesday, 12'th May 2021
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that two poster presentations of new clinical data and analyses
Geron Corporation (GERN) CEO John Scarlett on Q1 2021 Results - Earnings Call Transcript
10:39pm, Monday, 10'th May 2021
Geron Corporation (GERN) CEO John Scarlett on Q1 2021 Results - Earnings Call Transcript
Geron: Q1 Earnings Insights
04:47pm, Monday, 10'th May 2021
Shares of Geron (NASDAQ:GERN) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 12.50% over the past year to ($0.09), which missed the estim
SHAREHOLDER ALERT: Geron Corporation (GERN) Officers and Directors Under Investigation for False Statements and Insider Trading
09:30am, Monday, 19'th Apr 2021
SAN FRANCISCO, April 19, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Geron Corporation (NASDAQ: GERN) relating to pos
Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat
10:41am, Wednesday, 14'th Apr 2021
Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.
